The European Journal of Health Economics

Order information:
Web: http://link.springer.de/orders.htm
Download restrictions: Access to the full text of the articles in this series is restricted.
Editor: J.-M.G.v.d. Schulenburg
For technical questions regarding this series, please contact (Christopher F Baum)
Series handle: repec:spr:eujhec

2009, Volume 10, Issue 4

• 357-359 Ten arguments for a societal perspective in the economic evaluation of medical innovations
  by Bengt Jönsson [Downloadable! (restricted)]
• 361-369 The socioeconomic costs of mental illness in Spain
  by Juan Oliva-Moreno & Julio López-Bastida & Angel Montejo-González & Rubén Osuna-Guerrero & Beatriz Duque-González [Downloadable! (restricted)]
• 371-388 Can Mediterranean diet really influence obesity? Evidence from propensity score matching
  by Andreas Drichoutis & Panagiotis Lazaridis & Rodolfo Nayga [Downloadable! (restricted)]
• 389-397 Importance of sociodemographic and morbidity aspects in measuring health-related quality of life: performances of three tools
  by Cecilia Quercioli & Gabriele Messina & Emanuela Barbini & Giovanni Carriero & Mara Fanì & Nicola Nante [Downloadable! (restricted)]
• 399-407 GPs as citizens’ agents: prescription behavior and altruism
  by Kim Olsen & Dorte Gyrd-Hansen & Andreas Boegh & Sofie Hansen [Downloadable! (restricted)]
• 409-419 Estimating the cost related to surveillance of colorectal cancer in a French population
  by Catherine Lejeune & Christine Binquet & Franck Bonnetain & Amel Mahboubi & Michal Abrahamowicz & Thierry Moreau & Maria Raikou & Laurent Bedenne & Catherine Quantin & Claire Bonithon-Kopp [Downloadable! (restricted)]
• 421-428 Perceived job security and sickness absence: a study on moral hazard
  by Jahangir Khan & Clas Rehnberg [Downloadable! (restricted)]
• 429-436 The lack of theoretical support for using person trade-offs in QALY-type models
  by Lars Østerdal [Downloadable! (restricted)]
• 437-453 Contractual design and PPPs for hospitals: lessons for the Portuguese model
  by Pedro Barros & Xavier Martinez-Giralt [Downloadable! (restricted)]
• 455-465 Alcohol and labor supply: the case of Iceland
  by Tinna Asgeirsdottir & Kerry McGeary [Downloadable! (restricted)]
• 467-474 Private expenditure and the role of private health insurance in Greece: status quo and future trends
  by Olga Siskou & Daphne Kaitelidou & Charalampos Economou & Peter Kostagiolas & Lycourgos Liaropoulos [Downloadable! (restricted)]

• 239-242 Why the econometrician is in good spirits: a workshop through the looking glass
  by Carl Lyttkens [Downloadable! (restricted)]
• 243-254 Exploring spatial patterns in general practice expenditure
  by Mickael Bech & Jørgen Lauridsen [Downloadable! (restricted)]
• 255-265 Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study
  by Douglas Taylor & Ankur Pandya & David Thompson & Paula Chu & Jennifer Graff & James Shepherd & Nanette Wenger & Heiner Greten & Rafael Carmena & Michael Drummond & Milton Weinstein [Downloadable! (restricted)]
• 267-273 Cost of skin cancer in England
  by S. Morris & B. Cox & N. Bosanquet [Downloadable! (restricted)]
• 275-285 The economic costs of Group B Streptococcus (GBS) disease: prospective cohort study of infants with GBS disease in England
  by Elizabeth-Ann Schroeder & Stavros Petrou & Gail Balfour & Oya Edamma & Paul Heath [Downloadable! (restricted)]
• 287-297 The cost of resistance: incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals
  by Ansgar Resch & Michael Wilke & Christian Fink [Downloadable! (restricted)]
• 299-308 Hybrid risk adjustment for pharmaceutical benefits
  by Manuel García-Goñi & Pere Ibern & José Inoriza [Downloadable! (restricted)]
• 309-321 Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach
  by Bastian Haß & Juliane Lungershausen & Nadine Hertel & Barbara Poulsen Nautrup & Wioletta Kotowa & Hiltrud Liedgens [Downloadable! (restricted)]
• 323-328 Material versus social deprivation and health: a case study of an urban area
  by Angela Testi & Enrico Ivaldi [Downloadable! (restricted)]
• 329-336 Modelling health expenditure at the household level in Greece
  by Manos Matsaganis & Theodore Mitrakos & Panos Tsakloglou [Downloadable! (restricted)]
• 337-346 Total costs of injury from accidents in the home and during education, sports and leisure activities: estimates for Norway with assessment of uncertainty
  by Knut Veisten & Åse Nossum & Juned Akhtar [Downloadable! (restricted)]
• 347-355 The economics of cochlear implant management in France: a multicentre analysis
  by Laurent Molinier & Hélène Bocquet & Vanina Bongard & Bernard Fraysse [Downloadable! (restricted)]

• 121-123 Is there a “continental” view of health economics evaluation?
  by Claude Pen [Downloadable! (restricted)]
• 125-133 Pesticides and farmer health in Nicaragua: a willingness-to-pay approach to evaluation
  by Hildegard Garming & Hermann Waibel [Downloadable! (restricted)]
• 135-148 The income distributive implications of recent private health insurance policy reforms in Australia
  by Alfons Palangkaraya & Jongsay Yong & Elizabeth Webster & Peter Dawkins [Downloadable! (restricted)]
• 149-155 International comparison of orthotic brace prices
  by Steven Simoens & Paul Guillaume & Ingrid Moldenaers & Antony Depoorter & Sandra Coster & Dirk den Steen & Stefaan Sande & Hans Debruyne & Dirk Ramaekers & Murielle Lona [Downloadable! (restricted)]
• 157-165 Guidelines for completing the EURONHEED transferability information checklists
  by John Nixon & Stephen Rice & Michael Drummond & Stephanie Boulenger & Philippe Ulmann & Gerard Pouvourville [Downloadable! (restricted)]
• 167-178 The labor supply of registered nurses in Finland: the effect of wages and working conditions
  by T. Kankaanranta & P. Rissanen [Downloadable! (restricted)]
• 179-186 Patient characteristics and fairness
  by Hannu Valtonen [Downloadable! (restricted)]
• 187-196 Can we assume that research participants are utility maximisers?
  by Gethin Griffith & Val Morrison & J. Williams & Rhiannon Edwards [Downloadable! (restricted)]
• 197-206 Activity-based funding for National Health Service hospitals in England: managers’ experience and expectations
  by Jonathan Sussex & Shelley Farrar [Downloadable! (restricted)]
• 207-215 Quality choice in a health care market: a mixed duopoly approach
  by Yasuo Sanjo [Downloadable! (restricted)]
• 217-226 Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort
  by Ulf-Göran Gerdtham & L. Andersson & Åsa Ericsson & Sixten Borg & Sven-Arne Jansson & Eva Rönmark & Bo Lundbäck [Downloadable! (restricted)]
• 227-231 Factors affecting nurses’ decision to get the flu vaccine
  by Shosh Shahrabani & Uri Benzion & Gregory Yom Din [Downloadable! (restricted)]
• 233-236 Response to the expertise: Procedures and methods of benefit assessments for medicines in Germany, by Geertruida E. Bekkering and Jos Kleijnen
  by Klaus Koch & Stefan Lange [Downloadable! (restricted)]
• 237-238 Procedures and methods of benefit assessments for medicines in Germany: give the child a name
  by Holger Schünemann & Regina Kunz & Yngve Falck-Ytter & Nancy Santesso [Downloadable! (restricted)]

• 1-3 Can we afford to ignore missing data in cost-effectiveness analyses?
  by Andrea Marshall & Lucinda Billingham & Stirling Bryan [Downloadable! (restricted)]
• 5-13 Health care costs, work productivity and activity impairment in non-malignant chronic pain patients
  by Christian Kronborg & Gitte Handberg & Flemming Axelsen [Downloadable! (restricted)]
• 15-23 SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility
  by Richard Grieve & Marina Grishchenko & John Cairns [Downloadable! (restricted)]
• 25-38 Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects
  by Christa Claes & Ralf Reinert & Johann-Matthias Schulenburg [Downloadable! (restricted)]
• 39-45 Comparing methodologies for the cost estimation of hospital services
  by S. Tan & F. Rutten & B. Ineveld & W. Redekop & L. Hakkaart-van Roijen [Downloadable! (restricted)]
• 47-55 Cost utility analysis of knee prosthesis with complete microprocessor control (C-leg) compared with mechanical technology in trans-femoral amputees
  by Simone Gerzeli & Aleksandra Torbica & Giovanni Fattore [Downloadable! (restricted)]
• 57-63 The relationship between the Balanced Budget Act and length of stay for Medicare patients in US hospitals
  by Mustafa Younis & Dana Forgione [Downloadable! (restricted)]
• 65-79 Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany
  by Dirk Schürmann & Sonja Sorensen & Erwin Cock & Sandeep Duttagupta & Ansgar Resch [Downloadable! (restricted)]
• 81-91 A comparison between willingness to pay and willingness to give up time
  by Debby Helvoort-Postulart & Carmen Dirksen & Alfons Kessels & Jos Engelshoven & M. Myriam Hunink [Downloadable! (restricted)]
• 93-101 The quality of life of Palestinians living in chronic conflict: assessment and determinants
  by Awad Mataria & Rita Giacaman & Angelo Stefanini & Nirmala Naidoo & Paul Kowal & Somnath Chatterji [Downloadable! (restricted)]
• 103-109 Do quality-adjusted life years take account of lost income? Evidence from an Australian survey
  by Jeff Richardson & Stuart Peacock & Angelo Iezzi [Downloadable! (restricted)]
• 111-119 An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event
  by Manouchehr Tavakoli & Neil Pumford & Mark Woodward & Alex Doney & John Chalmers & Stephen MacMahon & Ronald MacWalter [Downloadable! (restricted)]

• 311-312 Health technology assessment: for whom the bell tolls?
  by Livio Garattini & Gianluigi Casadei [Downloadable! (restricted)]
• 313-323 Decision-analytical modelling in health-care economic evaluations
  by Xin Sun & Thomas Faunce [Downloadable! (restricted)]
• 325-331 Discarded cellular components and the technical efficiency of component preparation
  by Marketta Veihola & Pekka Aroviita & Riitta Kekomäki & Miika Linna & Harri Sintonen [Downloadable! (restricted)]
• 333-342 Nurses’ intentions to leave nursing in Finland
  by T. Kankaanranta & P. Rissanen [Downloadable! (restricted)]
• 343-349 Lessons for health care reform from the less developed world: the case of the Philippines
  by Konrad Obermann & Matthew Jowett & Juanito Taleon & Melinda Mercado [Downloadable! (restricted)]
• 351-360 The societal cost of alcohol consumption: an estimation of the economic and human cost including health effects in Sweden, 2002
  by Johan Jarl & Pia Johansson & Antonina Eriksson & Mimmi Eriksson & Ulf-G. Gerdtham & Örjan Hemström & Klara Selin & Leif Lenke & Mats Ramstedt & Robin Room [Downloadable! (restricted)]
• 361-367 Cost of care of colorectal cancers according to health care patterns and stage at diagnosis in France
  by Laurence Clerc & Valérie Jooste & Catherine Lejeune & Bernard Schmitt & Patrick Arveux & Catherine Quantin & Jean Faivre & Anne-Marie Bouvier [Downloadable! (restricted)]
• 369-380 Health insurance theory: the case of the missing welfare gain
  by John Nyman [Downloadable! (restricted)]
• 381-384 Economic evaluation of innovative technologies in health care should include a short-run perspective
  by Eddy Adang [Downloadable! (restricted)]
• 385-392 Public funding for community-based skilled delivery care in Indonesia: to what extent are the poor benefiting?
  by Tim Ensor & Mardiati Nadjib & Zahid Quayyum & Amila Megraini [Downloadable! (restricted)]
• 393-403 Expanding access to primary care without additional budgets? A case study from Burkina Faso
  by Paul Marschall & Steffen Flessa [Downloadable! (restricted)]
• 405-416 Redistributive effects in public health care financing
  by Ivonne Honekamp & Daniel Possenriede [Downloadable! (restricted)]

• 205-207 IQWiG: an opportunity lost?
  by Bengt Jönsson [Downloadable! (restricted)]
• 209-219 Quality of life and cost-effectiveness of acupuncture treatment in patients with osteoarthritis pain
  by Thomas Reinhold & Claudia Witt & Susanne Jena & Benno Brinkhaus & Stefan Willich [Downloadable! (restricted)]
• 221-228 Economic consequences of near-patient test results: the case of tests for the Helicobacter Pylori bacterium in dyspepsia
  by Siri Fauli & Geir Thue [Downloadable! (restricted)]
• 229-236 The cost of treating high blood pressure in general practice in France
  by Yaël Tibi-Levy & Gérard Pouvourville & Jérémie Westerloppe & Marion Bamberger [Downloadable! (restricted)]
• 237-249 An assessment of the discriminative ability of the EQ-5Dindex, SF-6D, and EQ VAS, using sociodemographic factors and clinical conditions
  by Garry Barton & Tracey Sach & Michael Doherty & Anthony Avery & Claire Jenkinson & Kenneth Muir [Downloadable! (restricted)]
• 251-259 Estimating the expected value of partial perfect information: a review of methods
  by Doug Coyle & Jeremy Oakley [Downloadable! (restricted)]
• 261-264 Choice determinants of the mobility in the Dutch health insurance market
  by Ilaria Mosca & Anoushka Schut-Welkzijn [Downloadable! (restricted)]
• 265-274 Predisposing factors for early retirement in patients with Schizophrenia in Germany
  by Reinhard Schnabel & Heiko Friedel & Andreas Erfurth & Matthias Angermayer & Johannes Clouth & Florian Eichmann [Downloadable! (restricted)]
• 275-284 Preferences and utilities for the symptoms of moderate to severe allergic asthma
  by Andrew Lloyd & Scott Doyle & Sarah Dewilde & Florian Turk [Downloadable! (restricted)]
• 285-292 In pursuit of QALY weights for relatives: empirical estimates in relatives caring for older people
  by Thomas Davidson & Barbro Krevers & Lars-Åke Levin [Downloadable! (restricted)]
• 293-304 A theoretical and empirical investigation of nutritional label use
  by Andreas Drichoutis & Panagiotis Lazaridis & Rodolfo Nayga & Maria Kapsokefalou & George Chryssochoidis [Downloadable! (restricted)]
• 305-310 Pricing and reimbursement of pharmaceuticals in Italy
  by Pietro Folino-Gallo & Simona Montilla & Mario Bruzzone & Nello Martini [Downloadable! (restricted)]

• 99-101 The CHESME Health Economic Evaluations Database (CHESME HEED) project
  by Dimitrios Rovithis & Lycurgus Liaropoulos [Downloadable! (restricted)]
• 103-115 Costing maternal health services in South Tanzania
  by Claudia Both & Albrecht Jahn & Steffen Fleßa [Downloadable! (restricted)]
• 117-125 Primary physicians’ response to changes in fees
  by Jostein Grytten & Fredrik Carlsen & Irene Skau [Downloadable! (restricted)]
• 127-136 The search for good compliance: economic aspects of a conveyed combination pharmaco-therapy, exemplified by an osteoporosis therapy
  by Peter Oberender & Jürgen Zerth [Downloadable! (restricted)]
• 137-145 Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD
  by Susan Griffin & Helen Weatherly & Gerry Richardson & Mike Drummond [Downloadable! (restricted)]
• 147-156 The role of non-need factors in individual GP utilisation analysis and their implications for the pursuance of equity: a cross-country comparison
  by P. McGregor & P. McKee & C. O’Neill [Downloadable! (restricted)]
• 157-163 Eligibility for free GP care, “need” and GP visiting in Ireland
  by A. Nolan & B. Nolan [Downloadable! (restricted)]
• 165-170 Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial
  by Hans Janka & Barbara Högy [Downloadable! (restricted)]
• 171-183 Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
  by Jonathan Karnon & Thomas Delea & Vicki Barghout [Downloadable! (restricted)]
• 185-191 The impact of generic substitution on price competition in Finland
  by Ville Aalto-Setälä [Downloadable! (restricted)]
• 193-201 Spillover of cause-specific longevity interventions: an independent mortality risk model
  by Liqun Liu [Downloadable! (restricted)]
• 203-203 Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance
  by Barbara Högy & Heinz-Otto Keinecke & Michael Borte [Downloadable! (restricted)]

• 1-6 Alcohol consumption in the EU: health economics and policy issues under a permanent debate
  by Fernando Antoñanzas & Roberto Rodríguez-Ibeas & Emilio Barco & Manuel Ramírez & Mariola Pinillos [Downloadable! (restricted)]
• 5-29 Procedures and methods of benefit assessments for medicines in Germany
  by Geertruida Bekkering & Jos Kleijnen [Downloadable! (restricted)]
• 7-15 Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects
  by Adam Lloyd & Nishma Patel & David Scott & Claus Runge & Christa Claes & Markus Rose [Downloadable! (restricted)]
• 17-22 Estimation and comparison of ostomy appliance costs with tariffs in Belgium
  by Veerle Vanleene & Luc Maré & Ingrid Moldenaers & Hans Debruyne & Steven Simoens & Dirk Steen & Dirk Ramaekers [Downloadable! (restricted)]
• 23-32 Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia
  by Ramon Sabes-Figuera & José Segú & Jaume Puig-Junoy & Antoni Torres [Downloadable! (restricted)]
• 31-43 Biostatistical aspects for the use of evidence based medicine in health technology assessment
  by Nick Freemantle [Downloadable! (restricted)]
• 33-39 Vaccination versus “wait and treat”: how to subsidize them?
  by Louis Eeckhoudt & Maurice Marchand & Pierre Pestieau & Gwenaël Piaser [Downloadable! (restricted)]
• 41-50 The differences in characteristics between health-care users and non-users: implication for introducing community-based health insurance in Burkina Faso
  by Hengjin Dong & Adjima Gbangou & Manuela Allegri & Subhash Pokhrel & Rainer Sauerborn [Downloadable! (restricted)]
• 51-61 Work environment satisfaction and employee health: panel evidence from Denmark, France and Spain, 1994–2001
  by Nabanita Datta Gupta & Nicolai Kristensen [Downloadable! (restricted)]
• 63-67 Does greater exposure to own-health data make a difference on the visual analog scale?
  by Amir Shmueli & David Messika & Havi Murad & Laurence Freedman [Downloadable! (restricted)]
• 69-78 Willingness to pay for a reduction in mortality risk after a myocardial infarction: an application of the contingent valuation method to the case of eplerenone
  by Jose-Luis Pinto-Prades & Veronica Farreras & Jaime de Bobadilla [Downloadable! (restricted)]
• 79-86 Factors influencing hospital costs of lung cancer patients in Northern Ireland
  by Ian Fleming & Pauline Monaghan & Anna Gavin & Ciaran O’Neill [Downloadable! (restricted)]
• 87-97 Pharmaceutical pricing and reimbursement reforms in Greece
  by John Yfantopoulos [Downloadable! (restricted)]
• 1-3 Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy
  by Thomas Müller [Downloadable! (restricted)]

• 33-34 Patient access to rheumatoid arthritis treatments
  by Bengt Jönsson & Gisela Kobelt & Josef Smolen [Downloadable! (restricted)]
• 35-38 Patient access to rheumatoid arthritis treatments
  by Bengt Jönsson [Downloadable! (restricted)]
• 39-47 The burden of rheumatoid arthritis and access to treatment: a medical overview
  by J. Smolen & D. Aletaha [Downloadable! (restricted)]
• 49-60 The burden of rheumatoid arthritis and access to treatment: health burden and costs
  by J. Lundkvist & F. Kastäng & G. Kobelt [Downloadable! (restricted)]
• 61-86 The burden of rheumatoid arthritis and access to treatment: uptake of new therapies
  by B. Jönsson & G. Kobelt & J. Smolen [Downloadable! (restricted)]
• 87-93 The burden of rheumatoid arthritis and access to treatment: determinants of access
  by J. Lundqvist & F. Kastäng & G. Kobelt & B. Jönsson [Downloadable! (restricted)]
• 95-106 The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments
  by G. Kobelt & B. Jönsson [Downloadable! (restricted)]

• 301-304 Tobacco policies in the European Union: a need for state and continental harmonisation?
  by Fernando Antoñanzas & Roberto Rodríguez [Downloadable! (restricted)]
• 305-312 Foreign direct investment in the health care sector and most-favoured locations in developing countries
  by J. Outreville [Downloadable! (restricted)]
• 313-323 Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery
  by Jonas Lundkvist & David Bergqvist & Bengt Jönsson [Downloadable! (restricted)]
• 325-332 The impact of home hospitalization on healthcare costs of exacerbations in COPD patients
  by Jaume Puig-Junoy & Alejandro Casas & Jaume Font-Planells & Joan Escarrabill & Carme Hernández & Jordi Alonso & Eva Farrero & Gemma Vilagut & Josep Roca [Downloadable! (restricted)]
• 333-337 Pricing matrix model: dealing with uncertainty
  by Mark Nuijten [Downloadable! (restricted)]
• 339-346 The incidence and cost of cardiac surgery adverse events in Australian (Victorian) hospitals 2003–2004
  by Jonathon Ehsani & Stephen Duckett & Terri Jackson [Downloadable! (restricted)]
• 347-357 Assessment of the pharmaceutical market in Poland after accession to the European Union
  by Patricia Willert [Downloadable! (restricted)]
• 359-359 Costs and quality of life in multiple sclerosis in The Netherlands
  by Gisela Kobelt & Jenny Berg & Peter Lindgren & Bert Anten & Mattias Ekman & Peter Jongen & Chris Polman & Bernard Uitdehaag [Downloadable! (restricted)]

• 179-179 Editor’s note
  by J.-Matthias Graf von der Schulenburg & Wolfgang Greiner [Downloadable! (restricted)]
• 181-193 Innovation in hospitals: a survey of the literature
  by Faridah Djellal & Faïz Gallouj [Downloadable! (restricted)]
• 195-212 Risk adjustment policy options for casemix funding: international lessons in financing reform
  by Kathryn Antioch & Randall Ellis & Steve Gillett & Daniel Borovnicar & Ric Marshall [Downloadable! (restricted)]
• 213-223 Incorporating efficiency in hospital-capacity planning in Germany
  by Ludwig Kuntz & Stefan Scholtes & Antonio Vera [Downloadable! (restricted)]
• 225-236 Variations in activity and practice patterns: a French study for GPs
  by Sophie Béjean & Christine Peyron & Renaud Urbinelli [Downloadable! (restricted)]
• 237-243 Income-related health inequality in Belgium: a longitudinal perspective
  by Ann Lecluyse [Downloadable! (restricted)]
• 245-251 Economic impact of shifting the locus of care for neuropathic pain from specialists to general practitioners
  by Ariel Berger & Piotr Kramarz & Gry Kopperud & John Edelsberg & Gerry Oster [Downloadable! (restricted)]
• 253-266 Patient access to pharmaceuticals: an international comparison
  by Joshua Cohen & Laura Faden & Susan Predaris & Brian Young [Downloadable! (restricted)]
• 267-277 Supplier-induced demand: re-examining identification and misspecification in cross-sectional analysis
  by Stuart Peacock & Jeffrey Richardson [Downloadable! (restricted)]
• 279-285 Is there an association between economic performance and public satisfaction in health care?
  by Eddy Adang & George Borm [Downloadable! (restricted)]
• 287-295 Why do patients bypass the nearest hospital? An empirical analysis for orthopaedic care and neurosurgery in the Netherlands
  by Marco Varkevisser & Stéphanie Geest [Downloadable! (restricted)]
• 297-300 Economic aspects of the new Spanish laws on pharmaceutical preparations
  by Fernando Antoñanzas & Juan Oliva & Mariola Pinillos & Carmelo Juàrez [Downloadable! (restricted)]

• 83-88 The time for cost-effectiveness in the new European Union member states: the development and role of health economics and technology assessment in the mirror of the Hungarian experience
  by László Gulácsi [Downloadable! (restricted)]
• 89-95 Pharmacoeconomic studies in Italy: a critical review of the literature
  by D. Cornago & L. Li Bassi & P. Compadri & L. Garattini [Downloadable! (restricted)]
• 97-103 The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management
  by Vesna Bjegovic & Zorica Terzic & Jelena Marinkovic & Nebojsa Lalic & Sandra Sipetic & Ulrich Laaser [Downloadable! (restricted)]
• 105-110 Patients’ willingness to pay for electronic communication with their general practitioner
  by Trine Bergmo & Silje Wangberg [Downloadable! (restricted)]
• 111-121 Systematic review of economic evaluations and cost analyses of guideline implementation strategies
  by Luke Vale & Ruth Thomas & Graeme MacLennan & Jeremy Grimshaw [Downloadable! (restricted)]
• 123-135 Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain
  by Maureen Rutten-van Mölken & Jan Oostenbrink & Marc Miravitlles & Brigitta Monz [Downloadable! (restricted)]
• 137-144 The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49
  by Richard Norman & D. Evans & Douglas Easton & Kenneth Young [Downloadable! (restricted)]
• 145-151 Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system
  by K. Le Lay & E. Myon & S. Hill & L. Riou-Franca & D. Scott & M. Sidhu & D. Dunlop & R. Launois [Downloadable! (restricted)]
• 153-160 An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany
  by Sara Sheriff & K. Petry & Hans Ikenberg & Geoffrey Crouse & Peter Mazonson & Christopher Santas [Downloadable! (restricted)]
• 161-168 Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis
  by Andrew Palmer & William Valentine & Joshua Ray & Stephane Roze & Noemi Muszbek [Downloadable! (restricted)]
• 169-170 Comment on: Should we really worry about “launch delays” of new drugs in OECD countries? by L. Garatinni and S. Ghislandi
  by Joshua Cohen [Downloadable! (restricted)]
• 171-171 Should we really worry about “launch delays” of new drugs in OECD countries? Reply to J Cohen
  by Livio Garattini [Downloadable! (restricted)]
• 173-177 Discussion point: should governments buy drug patents?
  by Juan Llano [Downloadable! (restricted)]

• 1-3 Should we really worry about “launch delays” of new drugs in OECD countries?
  by Livio Garattini & Simone Ghislandi [Downloadable! (restricted)]
• 3-3 Technology assessment in the German context
  by Michael Drummond [Downloadable! (restricted)]
• 5-31 Methods for determining cost-benefit ratios for pharmaceuticals in Germany
  by J.- Graf v. d. Schulenburg & Christoph Vauth & Thomas Mittendorf & Wolfgang Greiner [Downloadable! (restricted)]
• 17-24 Better primary physician services lead to fewer hospital admissions
  by Fredrik Carlsen & Jostein Grytten & Julie Kjelvik & Irene Skau [Downloadable! (restricted)]
• 25-30 Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy
  by Peter Lindgren & Thomas Kahan & Neil Poulter & Martin Buxton & Patrick Svarvar & Björn Dahlöf & Bengt Jönsson [Downloadable! (restricted)]
• 31-39 Risk-adjusted capitation payments: how well do principal inpatient diagnosis-based models work in the German situation? Results from a large data set
  by Corinne Behrend & Florian Buchner & Michael Happich & Rolf Holle & Peter Reitmeir & Jürgen Wasem [Downloadable! (restricted)]
• 41-50 Long-term absenteeism due to sickness in Sweden. How long does it take and what happens after?
  by Daniela Andrén [Downloadable! (restricted)]
• 51-57 Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany
  by B. Brüggenjürgen & P. Lindgren & B. Ehlken & H.-J. Rupprecht & S. Willich [Downloadable! (restricted)]
• 59-65 A multilevel analysis on the determinants of regional health care expenditure: a note
  by Guillem López-Casasnovas & Marc Saez [Downloadable! (restricted)]
• 67-76 Resource use and costs associated with patients treated for depression in primary care
  by P. Sobocki & M. Ekman & H. Ågren & I. Krakau & B. Runeson & B. Mårtensson & B. Jönsson [Downloadable! (restricted)]
• 77-82 A public–private analysis of the new Dutch health insurance system
  by Hans Maarse & Yvette Bartholomée [Downloadable! (restricted)]
• 5-15 Cost of breast cancer in Sweden in 2002
  by Mathias Lidgren & Nils Wilking & Bengt Jönsson [Downloadable! (restricted)]
• 1-2 Economic evaluation for pharmaceuticals in Germany
  by Bengt Jönsson [Downloadable! (restricted)]

• 223-224 Time for a common standard for cost-effectiveness in Europe?
  by Bengt Jönsson [Downloadable! (restricted)]
• 225-230 Optional deductibles in social health insurance systems
  by Claudia Pütz & Christian Hagist [Downloadable! (restricted)]
• 231-237 A decomposition of income-related health inequality applied to EQ-5D
  by Jens Gundgaard & Jørgen Lauridsen [Downloadable! (restricted)]
• 238-246 Cost effectiveness of preventive home visits to the elderly
  by Christian Kronborg & Mikkel Vass & Jørgen Lauridsen & Kirsten Avlund [Downloadable! (restricted)]
• 247-254 Cost-benefit analysis of a plant sterol containing low-fat margarine for cholesterol reduction
  by A. Gerber & T. Evers & H. Haverkamp & K. Lauterbach [Downloadable! (restricted)]
• 255-264 Cost-effectiveness of the Danish smoking cessation interventions
  by Kim Olsen & Lone Bilde & Henrik Juhl & Niels Kjaer & Holger Mosbech & Torben Evald & Mette Rasmussen & Helle Hiladakis [Downloadable! (restricted)]
• 265-269 The demand for private health care under national health insurance
  by Y. Machnes [Downloadable! (restricted)]
• 270-275 Economic cost associated with type II diabetes in Spanish patients
  by Miguel Ballesta & Florentino Carral & Gabriel Olveira & José Girón & Manuel Aguilar [Downloadable! (restricted)]
• 276-284 Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany
  by Alan Brennan & Roberta Ara & Raimund Sterz & Bernd Matiba & Rito Bergemann [Downloadable! (restricted)]
• 285-289 Tests of stationarity and cointegration of health care expenditure and gross domestic product
  by Halil Kiymaz & Yasemin Akbulut & Ahmet Demir [Downloadable! (restricted)]
• 290-296 Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany
  by W. Greiner & K. Lehmann & S. Earnshaw & C. Bug & R. Sabatowski [Downloadable! (restricted)]

• 155-157 Risk-sharing agreements for innovative drugs
  by Gérard Pouvourville [Downloadable! (restricted)]
• 158-164 Nonmedical economic consequences attributable to visual impairment
  by Antoine Lafuma & Antoine Brezin & Francis Fagnani & Viviane Mimaud & Mounir Mesbah & Gilles Berdeaux [Downloadable! (restricted)]
• 165-172 A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany
  by Stephen Beard & Fiona Maciver & Johannes Clouth & Eckart Rüther [Downloadable! (restricted)]
• 173-178 Test-retest reliability of willingness to pay
  by Alan Shiell & Penelope Hawe [Downloadable! (restricted)]
• 179-184 The costs of schizophrenia in Spain
  by Juan Oliva-Moreno & Julio López-Bastida & Rubén Osuna-Guerrero & Angel Montejo-González & Beatriz Duque-González [Downloadable! (restricted)]
• 185-191 Health care in the CIS countries
  by Anatoly Pilyavsky & Matthias Staat [Downloadable! (restricted)]
• 192-194 Problems and costs associated with alcohol and drug abuse in emergency medicine
  by F.-X. Huber & T. Hackert & P. Meeder [Downloadable! (restricted)]
• 195-203 Determinants of household health expenditure on western institutional health care
  by Tin Su & Subhash Pokhrel & Adjima Gbangou & Steffen Flessa [Downloadable! (restricted)]
• 204-211 Price regulation and generic competition in the pharmaceutical market
  by Dag Dalen & Steinar Strøm & Tonje Haabeth [Downloadable! (restricted)]
• 212-217 Alcohol-related mortality, drinking behavior, and business cycles
  by Edvard Johansson & Petri Böckerman & Ritva Prättälä & Antti Uutela [Downloadable! (restricted)]
• 218-220 Decision models in the evaluation of psychotropic drugs
  by Corrado Barbui & Camilla Lintas [Downloadable! (restricted)]

• 55-64 Costs and quality of life in multiple sclerosis in The Netherlands
  by Gisela Kobelt & J. Berg & P. Lindgren [Downloadable! (restricted)]
• 89-90 Pharmaceutical policy in Italy
  by Livio Garattini & Dante Cornago [Downloadable! (restricted)]
• 91-98 The reasons of general practitioners for promoting colorectal cancer mass screening in France
  by Célia Berchi & Jean-Marc Dupuis & Guy Launoy [Downloadable! (restricted)]
• 99-106 Choices and utilization in dental care
  by Lien Nguyen & Unto Häkkinen [Downloadable! (restricted)]
• 107-113 Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer
  by Samuel Limat & Claire-Hélène Bracco-Nolin & Christine Legat-Fagnoni & Loic Chaigneau & Ulrich Stein & Bernard Huchet & Xavier Pivot & Marie-Christine Woronoff-Lemsi [Downloadable! (restricted)]
• 114-116 Health care and patients’ migration across Spanish regions
  by David Cantarero [Downloadable! (restricted)]
• 117-122 The future of imaging techniques for cancer patients in The Netherlands
  by Theo Postma & Janneke Alers & Sijmon Terpstra & Arjan Zuurbier [Downloadable! (restricted)]
• 123-128 Factors influencing the costs of emergency medical admissions to an Irish teaching hospital
  by Edward Moloney & Kathleen Bennett & Bernard Silke [Downloadable! (restricted)]
• 129-136 Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers
  by Hans-Georg Eichler & Sheldon Kong & Jean-Pierre Grégoire [Downloadable! (restricted)]
• 137-144 Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain
  by Fernando Antonanzas & Benoit Rive & Josep Badenas & Susana Gomez-Lus & Chantal Guilhaume [Downloadable! (restricted)]
• 145-146 Costs of chemotherapy in the treatment of colorectal cancer
  by F. Jansman & M. Postma [Downloadable! (restricted)]
• 147-151 A taxonomy of health utility assessment methods and the role for uncertainty analysis
  by Agota Szende & Caroline Schaefer [Downloadable! (restricted)]

• 5-6 The desirability and feasibility of economic studies of drugs post-launch
  by Michael Drummond & Anne Mason & Adrian Towse [Downloadable! (restricted)]
• 7-18 The relationship between health care expenditure and health outcomes
  by John Nixon & Philippe Ulmann [Downloadable! (restricted)]
• 19-29 Pharmacoeconomic modelling in schizophrenia
  by Karina Hansen & Christophe Lançon & Mondher Toumi [Downloadable! (restricted)]
• 30-36 Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients
  by Monica Merito & Patrizio Pezzotti [Downloadable! (restricted)]
• 37-45 Fixed budgets as a cost containment measure for pharmaceuticals
  by David Granlund & Niklas Rudholm & Magnus Wikström [Downloadable! (restricted)]
• 46-54 The Danish effect on Swedish alcohol costs
  by Johan Jarl & Ulf-G. Gerdtham & Carl Lyttkens & Thor Lithman & Juan Merlo [Downloadable! (restricted)]
• 55-65 Prospective casemix-based funding, analysis and financial impact of cost outliers in all-patient refined diagnosis related groups in three Belgian general hospitals
  by Magali Pirson & Dimitri Martins & Terri Jackson & Michèle Dramaix & Pol Leclercq [Downloadable! (restricted)]
• 66-71 Case-control analysis of the financial cost of medication errors in hospitalized patients
  by Jaime Pinilla & Carles Murillo & Genís Carrasco & Carlos Humet [Downloadable! (restricted)]
• 72-78 Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care
  by Steven Edwards & Helen Campbell & Jonathan Plumb [Downloadable! (restricted)]
• 79-83 Off-patent drugs in Italy
  by Livio Garattini & Simone Ghislandi [Downloadable! (restricted)]

Access and download statistics

Did you know? You can import bibliographic info in various formats into you bibliographic tool, or just into your word processor. See under "publisher info" on each abstract page.

This page was last updated on 2009-11-14.